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Change in the level of CuZn-superoxide ismutase (SOD) mRNA was examined using a molecular probe during differen- 
tiation of human monocytic leukemia U937 cells or promyelotic leukemia HL-60 cells induced by either 12-O-tetradeca- 
noyl-phorbol-13-acetate (TPA) or dimethylsulfoxide (DMSO). CuZn-SOD mRNA levels were found to decrease during 
the course of differentiation, and this response isspecific for differentiation, since the treatment ofhuman B cell leukemia 
cells or normal diploid fibroblasts with TPA failed to have any effect on the level of CuZn-SOD mRNA. The activity 
of CuZn-SOD in U937 cells also decreased during differentiation, but following that of the CuZn-SOD mRNA level. 
The expression of the CuZn-SOD gene is thus concluded to diminish during the differentiation ofHL-60 and U937 cells. 
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1. INTRODUCTION 
Human monocyt ic  leukemia U937 promyelot ic  
leukemia HL-60 cells are known to terminal ly dif- 
ferentiate into monocyte- l ike cells in the presence 
o f  TPA and HL-60 cells in DMSO to di f ferent iate 
into granulocyte- l ike cells [1,2]. Di f ferent iated 
ceils have various macrophage-  or  granulocyte- 
specific functions, such as phagocytosis ,  and Fc- 
receptors of  non-specif ic esterases (for review [3]). 
The expression o f  the proto-oncogene c-myc is 
d iminished uring the di f ferent iat ion of  HL-60 or 
U937 cells [4-7],  whereas that o f  c-sis and c-fms 
genes increases during TPA- induced dif ferentia-  
t ion [8]. Besides these phenotypic  changes, dif- 
ferent iated HL-60 and U937 cells produce 
superoxide anions [9]. 
The active oxygens which include superoxide 
anions are extremely toxic and clastogenic to cells 
[10], but we have recently observed that active ox- 
ygens can work as growth stimuli at appropr iate  
concentrat ions [11,12]. Similar f indings on the 
'pos i t ive '  effect of  active oxygens have been 
reported by Cerutt i  and his colleagues [13,14]. Ac- 
tive oxygens are also supposed to p lay a role in cell 
d i f ferent iat ion [15]. 
Superoxide dismutase (SOD) is thought to be 
one of  the key enzymes in control l ing superoxide 
anion and  other active oxygen levels [16], and 
some authors considered it to be involved in tissue 
development  [17]. It was thus considered pert inent 
to examine the expression of  SOD during the dif- 
ferent iat ion of  HL-60 or U937 cells. The present 
communicat ion  reports that during dif ferentia-  
t ion, there is a decrease in the level of  CuZn-SOD 
mRNA and its activity. 
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2. MATERIALS  AND METHODS 
2.1. Cells and chemicals 
U937, HL-60 and Raji cells were obtained from the Japanese 
Cancer Research Resources Bank and grown in RPMI-1640 
supplemented'with 10070 fetal bovine serum in 9507o air and 5070 
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CO2. Normal human fibroblast JHU-I cells were cultured as 
described previously [18]. Cells were plated at approx. 1 × 105 
cells/ml in 100 mm plastic dishes and treated with inducers 3
days after plating. 
TPA and 1-oleoyl-2-acetylglycerol (OAG) were obtained 
from Sigma Chemicals and Serdary Research Lab., respec- 
tively. 
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2.2. Analysis of RNA 
Total cellular RNA was extracted by the guanidinium-hot 
phenol method as described previously [19] and run on a 1.5070 
agarose gel containing 2.2 M formaldehyde. After transfer of 
the RNA to nylon membranes (HybOnd N, Amersham), the 
filters were hybridized with 32p-labeled molecular probes. 
Oligonucleotides for human CuZn-SOD cDNA corresponding 
to nucleotides 93-142 (50-mer) [20] and human extracellular 
SOD cDNA corresponding to nucleotides 70-119 (50-mer) [21] 
were synthesized and labeled with random primers and Klenow 
enzyme (Pharmacia). c-myc [18] and B-actin probes [19] were as 
described previously. 
2.3. Measurement of CuZn-SOD activity 
The cells were washed with phosphate-buffered saline and 
disrupted by sonication i  0.1 M KH2PO4, pH 8.2. CuZn-SOD 
activity was measured by the nitrite-kit method following the 
procedure of Oyanagi [22] which uses xanthine/xanthine ox- 
idase to produce Or and hydroxyamine/N-l-naphthylethyl- 
enediamine dihydrochloride + sulfanilic acid to produce color. 
The activity, assayed in the presence of5 mM KCN (Mn-SOD), 
was subtracted from total SOD activity and the value thus ob- 
tained was regarded to be the activity of CuZn-SOD. 
3. RESULTS AND DISCUSSION 
The level of CuZn-SOD mRNA was determined 
using Northern blot hybridization of total RNA 
extracted from monocytic leukemia U937 cells in- 
duced to differentiate by TPA.  RNA was frac- 
t ionated on a 1.5°70 agarose gel containing 
formaldehyde and hybridized with a synthetic 
ol igonucleotide probe specific for CuZn-SOD 
cDNA. The probe detected a single band of ap- 
proximately 0.7 kb in size (fig. 1). The amount  of 
CuZn-SOD mRNA was found to decrease during 
the course of differentiation of U937 cells treated 
with 50 ng /ml  of TPA,  whereas the amount  of/~- 
actin mRNA used as a reference remained essen- 
tially unchanged or increased only slightly. U937 
cells treated with TPA for 24 h were clearly shown 
to differentiate by morphological changes and the 
appearance of non-specific esterases and the Fc- 
receptor. Fractions of Fc-receptor- and non- 
specific esterase-positive cells were 11 o7o and 8.6o70, 
respectively, in undifferentiated cells and were in- 
actin 
Fig.1. Changes in the level of CuZn-SOD mRNA during 
differentiation of U937 cells. Cells were incubated with 
50 ng/ml TPA for the times indicated. Total RNA (20/Lg/lane) 
was extracted and run on an 1.5070 agarose gel containing 2.2 M 
formaldehyde. After being transferred tonylon membranes, the 
filters were hybridized with 32P-labeled human CuZn-SOD or 
~Y-actin probes. The arrows indicate the positions of 28 and 18 S 
rRNA. 
creased to 31°70 and 42°7o after treatment with 
50 ng /ml  TPA for 24 h. 
Protein kinase C is activated by TPA as well as 
by synthetic diglycerol, OAG [23], and this activa- 
t ion is thought o be essential for differentiation. 
Kreuter et al. [24], however, reported that HL-60 
cells were induced to differentiate by TPA but not 
by OAG.  To determine whether the decrease in 
CuZn-SOD mRNA level is correlated with dif- 
ferentiation, U937 cells were treated with either 
50 ng /ml  TPA or 50/zg/ml OAG. TPA treatment 
caused a dramatic decrease in the c-myc mRNA 
level which is known to be associated with dif- 
ferentiation of leukemia ceils, whereas OAG treat- 
ment failed to cause such a change (fig.2). 
CuZn-SOD mRNA levels in OAG-treated cells did 
254 
Volume 249, number 2 FEBS LETTERS June 1989 
TPA OAG 
0 12 24 0 2 24 (h)  
Cu,Zn--SOD 
Fig.2. Effect of OAG on the level of CuZn-SOD mRNA in 
U937 cells. Cells were incubated with 50 ng/ml of TPA or 50 ,ug 
OAG and processed as in fig. 1. 
(h~} 
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not undergo a detectable change in contrast to 
TPA-treated cells. To see whether the decrease in 
CuZn-SOD mRNA in differentiated U937 cells is 
unique to this particular cell line, its level in pro- 
myelotic leukemia HL-60 cells was examined. 
HL-60 cells differentiate into macrophage-like 
cells when treated with TPA and into granulocyte- 
like cells with DMSO. Levels of CuZn-SOD 
mRNA and c-myc were found to decrease by 
similar kinetics in cells treated with either TPA or 
DMSO (fig.3). 
TPA  treatment of B cell leukemia Raji cells or 
normal human diploid fibroblast JHU-1 cells 
failed to give rise to a detectable decrease in SOD 
mRNA (data not shown). 
In table 1, the changes in the activity of CuZn- 
SOD in crude extracts of U937 ceils following 
treatment with TPA are shown. The activity 
decreased after TPA treatment, but there was a lag 
period of about 12 h. 
In the present communication, evidence is 
presented of the decrease in CuZn-SOD mRNA in 
U937 and HL-60 cells treated with TPA or DMSO 
during differentiation, mRNA for extracellular 
SOD could not be detected in U937 or HL-60 cells 
by the synthetic oligonucleotide probe described in 
section 2, even though it was found in human 
fibroblasts (data not shown). 
SOD may perform some essential role in the 
e--myc 
Fig.3. Changes in the level of CuZn-SOD mRNA during 
differentiation of HL-60 cells. HL-60 cells were treated either 
with 50 ng/ml TPA or 1.5% DMSO for the times indicated, 
and total RNA was analyzed as described in the legends for 
rigA. 
metabolism of active oxygens [16,25]. The activity 
of CuZn-SOD is known to change during the pro- 
cess of differentiation. Recent findings indicate 
that this activity increases during differentiation of 
mouse erythroid leukemia cells [26] or during mus- 
cle and adipocyte differentiation of rat embryo 
cells [27]. CuZn-SOD activity is also known to in- 
crease during lung development [17] or oxidant 
stress [28]. On the other hand, myeloperoxidase 
activity is reported to be less in mature 
granulocytes than in immature HL-60 cells [29]. 
Differentiated U937 or HL-60 cells produce ac- 
tive oxygens [9,30], and the authors initially ex- 
pected that CuZn-SOD mRNA would increase 
during differentiation as a protective measure 
against he cytotoxic effects of active oxygens. The 
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Table l 
Change in CuZn-SOD activity during differentiation of U937 
cells 
Time of TPA-treatment CuZn-SOD activity 
(h) (U/mg protein) 
0 1.09 ± 0.12 a
6 1.18 ± 0.10 
12 1.22 _+ 0.13 
24 0.69 ± 0.24 
48 0.34 _+ 0.12 
a ±, standard eviation from triplicate assays 
decrease in CuZn-SOD mRNA followed by that of 
its activity, as observed in the present communica-  
t ion, may be biologically significant for the effi- 
cient product ion of active oxygens. 
Cancer cells generally possess less SOD than 
their normal  counterparts [31], and SOD and 
catalase activities are reported to decrease in 
mouse epidermis following treatment with TPA 
[32]. These findings along with the present results 
indicate that the level of  SOD is dynamical ly con- 
trolled, and its change may be biologically impor- 
tant in uti l ization of active oxygens, which we 
consider important signals for cellular growth as 
well as for differentiation. 
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